Tradelogiq Markets Inc. (“Tradelogiq”) was one of dozens of companies across Canada that recently donated to the Sunnybrook Foundation to support a clinical trial for a new treatment of COVID-19.

Sunnybrook is the logistical lead for a national clinical trial involving as many as 60 medical centers across Canada and the United States. The Convalescent Plasma for COVID-19 Research (“CONCOR-1”) trial is investigating the therapeutic use of plasma – the portion of blood that contains antibodies – from patients who have recovered from COVID-19. Scientists hope to prove that antibodies found in the plasma of recovered patients can bind to and neutralize the virus that causes COVID-19.

“We are active participants in the greater community, and by supporting this important clinical trial we hope to help make a difference in the fight against COVID-19,” said Laurence Rose, Chairman, and CEO of Tradelogiq.

CONCOR-1 will enroll 1,200 patients from participating medical centers across Canada and requires approximately 650 plasma donors. For this trial, patients who have completely recovered from COVID-19 donate their plasma as a potential treatment for patients who are acutely ill with the virus.